Relapsed myeloma: how the next line of treatment is chosen | CION Cancer Clinics

There are usually several. The next treatment is chosen mainly by what you have already had, how long it worked, and how fit you are now, and it often combines medicines from a family you have not yet been treated with.

Why myeloma tends to return

For most people, myeloma is a long-term condition that is controlled rather than removed. Even after a very good response, a small number of myeloma cells usually survive. Over time they can grow again, often in a form that has learned to resist the medicines used before. A relapse is disappointing, but it is an expected part of the illness for many people, and it does not mean treatment has run out.

What "the next line" means

Each new treatment plan started after the myeloma returns is called a line of treatment. Doctors think in sequences: which medicines to use now, and which to keep for later. The order matters, because what works less well after one medicine may work better after another.

Who decides, and how

Your haematologist leads the decision, ideally after discussing the case at a tumour board. At CION, Dr. Basudev Pokhrel and the haematology team review previous treatment records in detail before suggesting a plan, and coordinate with qualified centres where a therapy is not given on site.

Most next-line treatments combine two or three medicines, usually with a steroid. The names below are generic and are examples, not a recommendation for you.

Combinations using a different medicine family

Common choices include daratumumab or isatuximab, which are antibody drips, combined with pomalidomide, carfilzomib or bortezomib. If you have not had daratumumab before, it is often part of the next plan. Carfilzomib does not suit everyone with heart problems.

A second stem cell transplant

For some people whose first transplant gave a long period of control, a second one may be considered. It does not suit those who relapsed quickly after the first, or who are not fit enough.

Newer immune treatments

CAR-T cell therapy and bispecific antibodies, which help your own immune cells find myeloma, are options for people who have had several lines. Access in India is growing but limited, costs are high, and they carry serious risks such as infections and immune reactions. CION does not give CAR-T on site; the team can assess eligibility and coordinate referral.

Clinical trials and symptom care

A clinical trial may offer a new medicine. Radiotherapy to painful bones and palliative care, which means care focused on comfort and quality of life, can run alongside any of these.

It cannot tell you which treatment is right for you, or how long any treatment will control your myeloma. Those depend on details only your own records and tests can show. A drug name on its own says nothing about your outlook.

Questions worth asking

Ask whether this is a biochemical or clinical relapse, which medicine families are still open to you, what the aim of this line is, and what would be the plan if it does not work. Ask how often you will need to travel, and what the side effects mean for work and family life.

Cost and schemes

Costs vary widely between combinations, and some newer medicines are expensive. Aarogyasri, CGHS, ECHS, EHS, PM-JAY and cashless insurance may cover parts of treatment. Entitlements change, so check current rules, and ask about patient assistance programmes run by manufacturers.